

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁵ : A61K 9/50	A1	(11) International Publication Number: WO 90/04963 (43) International Publication Date: 17 May 1990 (17.05.90)
(21) International Application Number: PCT/GB89/01317 (22) International Filing Date: 3 November 1989 (03.11.89) (30) Priority data: 8826116.9 8 November 1988 (08.11.88) GB (71) Applicant (for all designated States except US): DANBIO-SYST UK LIMITED [GB/GB]; Unit 24, Heathcoat Building, Highfields Science Park, University Boulevard, Nottingham NG7 2QJ (GB). (72) Inventors; and (75) Inventors/Applicants (for US only) : ILLUM, Lisbeth [DK/GB]; 19 Cavendish Crescent North, The Park, Nottingham NG7 1BA (GB). WILLIAMS, Paul [GB/GB]; 41 Ranelagh Grove, Wollaton, Nottingham NG8 1HR (GB). CASTON, Antony, James [GB/GB]; 23 Hope Drive, The Park, Nottingham NG7 1DL (GB).		(74) Agent: BASSETT, Richard; Eric Potter & Clarkson, 14 Oxford Street, Nottingham NG1 5BP (GB). (81) Designated States: AT (European patent), BE (European patent), CH (European patent), DE (European patent), FR (European patent), GB, IT (European patent), JP, LU (European patent), NL (European patent), SE (European patent), US. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: ADHESIVE DRUG DELIVERY COMPOSITION (57) Abstract Adhesive material from the fimbriae (esp. Type 1) of bacteria or synthetic analogues or fragments thereof is combined with a drug to provide for attachment to the gut of a mammal, thereby prolonging the transit time of the drug through the gut. The 28kDa polypeptide from <i>E. coli</i> Type 1 fimbriae is the preferred adhesive material ("adhesin"). The drug is presented in a carrier such as albumin, a polylactide/glycolide copolymer or alginate microcapsules. The adhesin may be incorporated in the carrier during preparation thereof, adsorbed onto the carrier after preparation, or covalently linked thereto, for example with carbodiimide.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LJ	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				

ADHESIVE DRUG DELIVERY COMPOSITION

The present invention relates to a drug delivery composition and more particularly to a drug delivery composition for administration via the gastrointestinal tract.

The gastrointestinal (G.I.) tract is one of the major routes for the administration of pharmacological agents. Drugs are normally well absorbed from the intestines, and dosage forms such as capsules, tablets and suspensions are well accepted by the general population. In recent years there has been a tendency towards the development of controlled release dosage forms that will provide therapy over an extended period of time. Normally this would be once a day and it is believed that such a change in dosage regimen will reduce adverse reactions and side effects and also improve patient compliance.

The design and evaluation of controlled release dosage forms must, however, take into account the properties of the gastrointestinal tract, including the rapid transit of material through the small intestine, which is the important site for absorption for certain drugs. Recent work by Davis and others at Nottingham University has shown that this transit time can be of the

order of 3 hours or less. Thus the disadvantage of very long release times, for example 24 hours, is that the drug could have passed through the small intestine before being released and therefore its curative property could be effectively nullified.

A considerable advantage can be gained if the dosage form is held in the small intestine so that it will be well absorbed into the systemic circulation over a long period of time.

Recently, work has been done into investigating the use of synthetic polymers that may have muco- or bio-adhesive properties, for example those disclosed in WO 85/02092, such as cross-linked acrylic acid and methacrylic acid polymers. The problem with the use of synthetic polymers lies in the mode of action of such materials and in particular whether it is intended to attach dosage forms to the mucus, which should easily slough off, or to attach dosage forms to the glycocalyx or directly to the cell surface of the enterocyte. Various *in vitro* tests conducted with excised portions of stomach and oesophagus are not considered to be realistic in terms of *in vivo* environmental conditions and transit phenomena.

It is an object of preferred aspects of the present invention to provide a drug delivery system for use in the gastrointestinal tract which obviates the above disadvantages and maintains the drug in the G.I. tract, for example in the small intestine, for a prolonged period thereby allowing the drug to be released at a desired rate over this prolonged period. By extending the period, the drug can if required be released more slowly, which may lead to less severe adverse reactions and side effects.

The present invention therefore provides a drug delivery system including a plurality of particles containing active drug material, preferably size 20 microns or less, and incorporating on the outer surface of at least some of the particles a natural bioadhesive material such that in use the natural bioadhesive material will adhere to the wall of the gut, particularly the small intestine or large intestine as desired.

The term "drug" is used herein to include any pharmacologically active compound or antigen-comprising material.

The term "bioadhesive" is used to denote a material which adheres to the gut wall. The qualifying term "natural" is used herein to indicate material which is

isolated from the outside surfaces of micro-organisms or synthetically prepared versions thereof, or analogues or fragments of such material.

Such natural bioadhesive materials have been previously proposed for use in medicine in WO 88/07078, but only as immobilising materials for binding biological material to a carrier, for example binding a blood clotting agent to a carrier substance. There was no suggestion that the bioadhesives could be used to direct medicaments to the gut wall.

The micro-organisms from which the adhesive material is derived or to which it corresponds will generally be those found in the G.I. tract, especially the (small) intestine, of the mammal being treated. Such micro-organisms include *E. coli*, *Klebsiella* spp. and *Salmonella* spp.

Preferably, the bioadhesive material is obtained from *Escherichia coli*, especially a human G.I. tract infesting strain thereof, or corresponds to such material.

In the small intestine certain bacterial flora are found to adhere extremely well. *Escherichia coli*, for example, adheres via surface proteins called fimbriae (pili). *E. coli* strains express the following fimbrial types:-

- (a) Type 1 or 'common' fimbriae whose adhesive properties are inhibited by mannose (mannose-sensitive fimbriae).
- (b) P fimbriae (mannose-resistant).
- (c) Colonisation factor antigens (CFAI and CFAII) which are mannose-resistant.

The present invention is concerned particularly with class (a). These materials, when purified, can be identified by the ability to haemagglutinate guinea-pig erythrocytes in the absence but not in the presence of α -methylmannoside. In the case of Type 1 fimbriae from *E. coli*, the presence of a 17 kDa sub-unit protein may be detected on sodium dodecyl sulphate polyacrylamide gel electrophoresis after denaturation of fimbriae by saturated guanidine HCl. In other organisms, such as *Klebsiella* spp. the corresponding sub-unit may be slightly larger or smaller. Finally, Type 1 fimbriae material from a given organism would be expected to react

in Dot and Western Immunoblots with a polyclonal antiserum raised against the Type 1 fimbriae from the same organism. The various test methods for all three of these tests are standard.

Type 1 fimbrial material from *E. coli* has previously been isolated and shown to comprise polypeptides of molecular weights of about 14kDa, 17kDa and 28kDa. See, for example, Hanson & Brinton, *Nature* 332, 265 (1988) and Hanson *et al*, *J. Bact.* 170(8), 3350 (1988). The 28kDa polypeptide described therein is probably the same as the 29kDa FimH polypeptide described by Abraham *et al*, (1988) *Infect. & Immun.* 56(5), 1023-1029. This latter paper suggests using FimH in a vaccine to confer immunity against *E. coli* binding, but does not suggest using FimH to bind a drug or antigen to the gut wall. The 17kDa polypeptide is the major polypeptide. Since micro-organisms can adhere firmly in the gastrointestinal tract through this adhesion process (which may be through an interaction between the adhesive molecule ("adhesin") and sugar residues, eg mannosides, in the gastrointestinal tract) it is possible in accordance with the present invention to achieve similar adhesive effects by the isolation and purification of an individual adhesin polypeptide. When administered to rabbits the adhesin is seen to adhere to the gastrointestinal tract.

Alternatively, the larger bodies known as "fimbriosomes" may be used. These bodies are described in Abraham et al, *Infect. & Immun.* 56(5), 1023, (1988).

In the present invention adhesins and similar bioadhesive materials produced from micro-organisms are used to design and develop controlled release dosage forms with extended gastrointestinal residence. The delivery system preferably consists of small particles (a few microns in size) so that the adhesive is able to attach the particle to the wall of the gastrointestinal tract through sugar residue, lectin-mediated processes. The adhesins may be coated onto particles or covalently bound (grafted) onto the surface of the particle. A preferred adhesin is the bacterial adhesin obtained from *E. coli*, but there are many other adhesin-producing bacteria available, for example *Pseudomonas aeruginosa*.

It is also apparent that the adhesive characteristics of the fimbrial material do not necessarily reside in the complete fimbrial structure and that a suitably cleaved product or its synthetic equivalent comprising the correct sequence of amino acids demonstrates similar bioadhesive properties. The preparation of a peptide of this sort is described in Abraham & Beachey, *J. Bact.* 169(6), 2460, (1987). More specifically, the peptide consisted of residues 23-35 of *E. coli* Type 1 fimbrial

protein namely VDAGTVDDQTVQLGC (i.e. Val-Asp-Ala-Gly-Thr-Val-Asp-Gln-Thr-Val-Gln-Lys-Gly-Cys). Such a peptide may be made by conventional techniques.

Likewise, synthetic polymers with a similar structure to that of the adhesin will generally have the same effect in enhancing the interaction between the wall of the small intestine and administered colloidal particles. Purified adhesin materials or synthetic analogues may be used as macromolecular carriers where the drug is attached to the adhesin molecule directly and not necessarily within a microparticle.

The attachment of fimbriae to the surface of drug-containing particles may be by adsorption (hydrophobic region of peptide to hydrophobic surface of a suitable particle, for example polymeric microsphere, polystyrene, polymethylmethacrylate, polyalkylcyanoacrylate, emulsion (triglyceride)), or by covalent attachment. Mechanisms for linking proteins to microspheres are given in Illum & Jones, *Methods in Enzymology* 112, 67-84 (1985).

Other ways of attaching the protein include modification of a particle surface by adsorption or covalent attachment of suitable linking groups to which the protein may be subsequently attached. Examples here

include albumin, gelatin, dextran, alginate, polylactide/glycolide, polyhydroxy-butyrate, polyanhydride microspheres and liposomes.

Dry formulations are to be preferred but suspensions in a suitable vehicle (for example, polyethylene glycol or triglyceride oil) may also be used. An actual drug formulation preferably involves the preparation of a multiparticulate drug containing system (size preferably below 1 mm) such as a microsphere or microcapsule. Drug entrapment may be performed during preparation (e.g. emulsification, polymerisation) or after (remote loading).

The fimbrial material may be included in the particle preparation step (if it can be attached to the particle surface; proteins are good stabilizers of emulsions) or grafted onto the surface during a polymerization stage. Alternatively, the material may be attached by adsorption or covalent linkage after the particles have been prepared.

The concept is readily applicable to many, if not all, drugs given orally, including cephalosporins, chlorthiazide, isosorbide and frusemide (which are absorbed in the (upper) regions of the small intestines)

and peptides which are intended for absorption in the colon, for example insulin, growth hormone, calcitonin, interferon and tumour necrosis factor.

Preferred embodiments of the present invention will now be described by way of examples.

EXAMPLE 1

Type 1 fimbriae were obtained from *Escherichia coli* AD9777 by culturing in nutrient broth. Agglutination properties were checked using guinea pig red blood cells. The bacteria were collected by centrifugation and the fimbriae were removed by use of a microfluidizer apparatus (Microfluidics Corporation) in a manner described in more detail below. The crude preparation was centrifuged and freeze dried. The proteins were then characterized by SDS polyacrylamide gel electrophoresis. Antibodies to bacterial Type 1 fimbriae were raised in rabbits for subsequent use in analytical procedures (immunoblotting, ELISA).

The fimbrial proteins are obtained as follows. In order to simplify the harvesting of the fimbrial proteins and to ensure consistency in the preparation, a microfluidizer (Model M110, Microfluidics, Newton, Mass, USA.) was used. This is a high pressure homogeniser used conventionally for the preparation of emulsions. It is

based on the submerged jet theory in which two similar streams travelling at very high velocities interact in precisely defined microchannels. The interaction of the two streams, in this case bacterial suspensions, disrupts the cells. Having grown and isolated the bacteria, a 2% w/v suspension was made. This was then added to the microfluidizer and subjected to a series of increasing pressures: 500psi to 6000psi (3.4 to 41.4 MNm^{-2}). At each pressure the suspension was cycled through the apparatus four times, then spun in a cool centrifuge. The supernatant was collected and stored at 4°C and the pellet was resuspended and the process repeated at a higher pressure. Once the bacterial suspension became translucent it was assumed that the cells had been totally disrupted, hence no further increase in pressure was necessary. The supernatants were freeze-dried, and the proteins present were studied by SDS polyacrylamide gel electrophoresis (SDS-PAGE). The gel showed that at a pressure of 500 psi (3.4 MNm^{-2}) the majority of the fimbrial proteins were stripped off with little contaminating proteins present; at 6000psi (41.4 MNm^{-2}) the bacteria had been totally disrupted.

It is found that the purified fimbrial material can cause agglutination of red blood cells on its own or when attached to a model colloidal particle, polystyrene latex. This agglutination effect could be blocked using

mannose, indicating that the agglutination was, as expected, mediated by binding to a mannose-specific site (lectin-mediated).

EXAMPLE 2: IN VITRO BINDING

The ability of Type 1 fimbrial proteins to adhere to the small intestine was measured in an *in vitro* preparation of gut-sacs from the rat small intestine. A length of evacuated rat small intestine was tied at one end using a ligature, and then 1 ml of a fimbrial suspension (100ng/ml) carefully added. The fimbrial suspension was prepared from fimbriae obtained as above and suspended in phosphate buffered saline at pH7.4. Having tied the other end of the intestine, again with a ligature, to form a sac, it was incubated in a flask containing 20 ml of oxygenated incubation medium at 37°C. After 30 minutes the sac was removed and the fimbrial suspension sampled. The fimbrial content was assayed by the Dot-blot method. Each experiment was performed in triplet, with and without α -methyl mannoside.

The results from the Dot-blots indicated that the fimbrial proteins were depleted from the medium and were adhering to the intestine.

EXAMPLE 3: IN VIVO BINDING OF ADHESINS

Type 1 fimbrial proteins, prepared as above, were labelled with iodine-125, by the normal method for labelling proteins, the Iodogen method, to allow detection of the proteins in biological tissues easier.

A suspension of the iodide-125 labelled proteins was administered to the isolated small intestine of an anaesthetised fasted rat (300g adult Wistar). The animal was maintained in an anaesthetised state for two hours after which it was killed. The entire small intestine was removed and sectioned into 1cm. sections which were assessed for radioactivity using a gamma counter. An activity profile for each animal was plotted to show the distribution of the activity and the total amount of activity associated with the intestine was calculated. Co-administration of various adherence inhibitors showed that the activity was associated with the fimbrial proteins and not free iodine-125 released from the I-125 labelled fimbrial proteins. A total of 15-20% more activity was associated with the intestine when fimbrial proteins were added in the absence of inhibitors compared with their administration in the presence of inhibitors. Inhibitors used included unlabelled fimbrial proteins and α methyl-mannoside.

EXAMPLE 4: IN VIVO BINDING OF COATED PARTICLES

Following the work outlined in Example 3, model particles were coated with Type 1 fimbriae and these coated particles were administered to the intestine as described. The polystyrene particles used were labelled with iodide-125 by irradiating them in a cobalt-60 source in the presence of iodide-125. The particles were cleaned and coated with fimbrial proteins. An aliquot of particles were mixed with a suspension of fimbrial proteins for a 24 hour period at room temperature. After this time the particles were centrifuged and the supernatant discarded. The fimbrial coated particles (otherwise known as sensitised) were administered to an animal as previously described. The same procedure for assessing the results was used for the sensitised particles as for free fimbriae. The activity profiles and the total activity recovered were plotted. A mean total percentage of activity retained in the small intestine for each experimental series was calculated and this value for each was plotted. Student's "T"-tests on these values have also been calculated.

The results show that the sensitised particles significantly adhere to the small intestine of the rat. Values of the average percentage of activity recovered in the intestine range from 35 to 40%, with experimental

values 15 to 20% greater than the controls. Statistical analysis of this data shows it to be significant to 95% confidence limits.

FORMULATIONS

Albumin as carrier

The formulation is prepared by the following process. An aqueous albumin solution is added to the drug and the resulting aqueous solution is dispersed in oil (with a suitable surfactant) to provide a water-in-oil emulsion. The product is heated in order to denature and cross-link the albumin, thereby providing microspheres, which are then washed. Finally, fimbrial material is attached to the microspheres by adsorption or by covalent linkage (using carbodiimide or another bifunctional coupling agent).

Poly(lactide/glycolide) as carrier. A

poly(lactide/glycolide) copolymer is first dissolved in a solvent which is also a solvent for the drug and an oil-in-water type of emulsion is prepared using the resulting solution. Solvent is removed from the emulsion to leave solid microspheres containing the drug. Finally, fimbrial material is attached by adsorption or by

covalent linkages as above. Alternatively, the microspheres may be prepared using a double emulsion (water-in-oil) process.

Alginate Microcapsules. The drug is first dissolved in a sodium alginate solution and drops of alginate are added to calcium chloride solution to form microcapsules. These are then separated and the fimbrial material is attached to the surface of the microcapsules as above.

In all examples, the fimbrial material can alternatively be included in the emulsification stage, which may be advantageous, especially for the oil-water formulations. The entrapment of the pilus material in an emulsion or liposome may be achieved by linking the protein to a lipid (such as a fatty acid), to a phospholipid (such as phosphatidyl-ethanolamine) or to a steroid (such as cholesterol). The fatty portion should then fit well into the emulsion/liposome in an analogous manner to monoclonal antibodies, as is known in the art (see, for example, Illum & Jones, *op. cit.*).

If desired, the formulations of the invention may be coated with an enteric coating which will protect the drug and the adhesins from acidic or proteolytic digestion in the stomach and then dissolve, leaving the adhesins exposed for binding to the intestinal wall.

CLAIMS

1. A drug delivery composition comprising a drug and a natural bioadhesive material which material will bind to the gut of a mammal.
2. A composition according to Claim 1 wherein the drug is present as a plurality of particles.
3. A composition according to Claim 2 wherein the particles have an average diameter of 20 microns or less.
4. A composition according to Claim 2 or 3 wherein the adhesive material is covalently attached to the drug particles.
5. A composition according to any one of Claims 2-4 wherein a layer of the adhesive material substantially coats each particle.
6. A composition according to any one of the preceding claims wherein the adhesive material is found in the Type 1 adhesin of *E. coli*.
7. A composition according to Claim 6 wherein the adhesive material comprises the 28kDa polypeptide of *E. coli* adhesins.

8. A process for preparing a composition according to any one of the preceding claims comprising combining a drug, a carrier for the drug and a natural bioadhesive material, the adhesive material being such as to bind to the gut of a mammal.

9. A method of treating a mammal comprising administering orally to the mammal a composition according to any one of Claims 1 to 7.

INTERNATIONAL SEARCH REPORT

PCT/GB 89/01317

International Application No

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all)⁶

According to International Patent Classification (IPC) or to both National Classification and IPC

Int.Cl. 5 A61K9/50

II. FIELDS SEARCHED

Minimum Documentation Searched⁷

Classification System

Classification Symbols

Int.Cl. 5

A61K

Documentation Searched other than Minimum Documentation
to the Extent that such Documents are Included in the Fields Searched⁸III. DOCUMENTS CONSIDERED TO BE RELEVANT⁹

Category ¹⁰	Citation of Document, ¹¹ with indication, where appropriate, of the relevant passages ¹²	Relevant to Claim No. ¹³
Y	WO,A,8502092 (BIO-MIMETICS INC.) 23 May 1985 see page 6, line 13 - page 8, line 7 see page 28, line 22 - page 29, line 29 see page 42, line 4 - page 52, line 19 see page 55, line 31 - page 60, line 26; figures 5, 6 (cited in the application) ---	1-3, 5-9
Y	WO,A,8807078 (DR. MULLER-LIERHEIM) 22 September 1988 see the whole document, in particular page 2, lines 15 - 19 ---	1-3, 5-9
A	GB,A,2041517 (FUJI PHOTO FILM) 10 September 1980 see the whole document ---	4

⁹ Special categories of cited documents : ¹⁰

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

"&" document member of the same patent family

IV. CERTIFICATION

Date of the Actual Completion of the International Search

27 FEBRUARY 1990

Date of Mailing of this International Search Report

20. 03. 90

International Searching Authority

EUROPEAN PATENT OFFICE

Signature of Authorized Officer

T.K. WILLIS

**ANNEX TO THE INTERNATIONAL SEARCH REPORT
ON INTERNATIONAL PATENT APPLICATION NO.**

GB 8901317

SA 32449

This annex lists the patent family members relating to the patent documents cited in the above-mentioned international search report.
The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

15/03/90

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8502092	23-05-85	AU-B- 565354	10-09-87
		AU-A- 3618484	03-06-85
		EP-A- 0163696	11-12-85
		JP-T- 61500612	03-04-86
		US-A- 4615697	07-10-86
		US-A- 4795436	03-01-89

WO-A-8807078	22-09-88	DE-A- 3709101	29-09-88
		EP-A- 0349558	10-01-90

GB-A-2041517	10-09-80	JP-A- 55094636	18-07-80
		JP-A- 56072346	16-06-81
		JP-A- 56072347	16-06-81
		DE-A, C 3000483	17-07-80
		US-A- 4342739	03-08-82
